Cheryl Rivard is a Psychiatry physician. OpenAlex indexes 31 publications with 668 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
322 Frontier Blvd
Stanford, KY 404847730
Telephone
859-253-1686Registry record last updated 9 Jul 2007.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alkermes, Inc.Program year20251 payment
- Teva Pharmaceuticals USA, Inc.Program year20251 payment
- Teva Pharmaceuticals USA, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
89.6%SSRI43.5%Trazodone Hcl48%Sertraline Hcl26%Escitalopram Oxalate26%Part D<11 patientsAzaspirodecanedione derivatives20.9%Buspirone Hcl100%Part D<11 patients+ 2 more classes in this area
Cardiovascular
10.4%Central alpha-2 Adrenergic Agonist10.4%Clonidine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Flavor and Device Choices Among People Who Use ENDS: Results From the PATH Study
American Journal of Preventive Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”